Published in J Intern Med on March 01, 2014
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease | NCT01224106
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease | NCT01227564
Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (MCI) | NCT01300728
Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease | NCT01019421
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol (2015) 1.70
Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology (2015) 1.45
Body fluid biomarkers in Alzheimer's disease. Ann Transl Med (2015) 1.44
The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care. Alzheimers Res Ther (2016) 1.39
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 1.38
Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci (2015) 1.26
The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med (2015) 1.09
Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging (2015) 1.02
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries. Front Pharmacol (2014) 0.98
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry (2014) 0.97
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Gains in cognition through combined cognitive and physical training: the role of training dosage and severity of neurocognitive disorder. Front Aging Neurosci (2015) 0.88
Alzheimer's disease: experimental models and reality. Acta Neuropathol (2016) 0.88
Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides. EMBO Mol Med (2016) 0.87
The flaws and human harms of animal experimentation. Camb Q Healthc Ethics (2015) 0.86
Microglial Aβ receptors in Alzheimer's disease. Cell Mol Neurobiol (2014) 0.86
Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. J Alzheimers Dis (2015) 0.83
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
The power of using functional fMRI on small rodents to study brain pharmacology and disease. Front Pharmacol (2015) 0.80
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther (2015) 0.80
Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther (2016) 0.79
"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials? Clin Pharmacol Ther (2016) 0.79
Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance. Acta Pharmacol Sin (2016) 0.79
Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Sci Rep (2016) 0.78
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis (2015) 0.78
Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β. Brain (2015) 0.78
Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo. Open Biol (2016) 0.78
Effects of green tea consumption on cognitive dysfunction in an elderly population: a randomized placebo-controlled study. Nutr J (2016) 0.77
Tau-mediated synaptic damage in Alzheimer's disease. Transl Neurosci (2015) 0.77
Application of hydrostatic CCC-TLC-HPLC-ESI-TOF-MS for the bioguided fractionation of anticholinesterase alkaloids from Argemone mexicana L. roots. Anal Bioanal Chem (2015) 0.77
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement (2015) 0.77
Nutritional strategies to optimise cognitive function in the aging brain. Ageing Res Rev (2016) 0.76
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? Lancet Psychiatry (2015) 0.76
Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clin Interv Aging (2015) 0.76
Hearing and Cognitive Impairment and the Role of the International Classification of Functioning, Disability and Health as a Rehabilitation Framework. Semin Hear (2016) 0.75
Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease. Alzheimers Res Ther (2015) 0.75
Effect of a Comprehensive Intervention on Plasma BDNF in Patients with Alzheimer's Disease. J Alzheimers Dis (2017) 0.75
Memory dysfunction. Continuum (Minneap Minn) (2015) 0.75
Are improper kinetic models hampering drug development? PeerJ (2014) 0.75
From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatr Dis Treat (2017) 0.75
Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα. Front Mol Neurosci (2017) 0.75
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol (2017) 0.75
An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci (2016) 0.75
Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innov Clin Neurosci (2017) 0.75
A Robust and Efficient Production and Purification Procedure of Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides. PLoS One (2016) 0.75
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. PLoS One (2015) 0.75
Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener (2017) 0.75
Editorial on, "Amyloid-beta clearance in Alzheimer's disease". Front Aging Neurosci (2014) 0.75
The need for thorough phase II studies in medicines development for Alzheimer's disease. Alzheimers Res Ther (2015) 0.75
Older patients are still under-represented in clinical trials of Alzheimer's disease. Alzheimers Res Ther (2016) 0.75
Looking for a generic inhibitor of amyloid-like fibril formation among flavone derivatives. PeerJ (2015) 0.75
HPTLC Fingerprinting and Cholinesterase Inhibitory and Metal-Chelating Capacity of Various Citrus Cultivars and Olea europaea. Food Technol Biotechnol (2016) 0.75
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope. J Alzheimers Dis (2016) 0.75
BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models. Sci Rep (2016) 0.75
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Front Aging Neurosci (2015) 0.75
Multi-targeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. J Med Chem (2017) 0.75
Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol. Proc Natl Acad Sci U S A (2017) 0.75
Categorizing Health Outcomes and Efficacy of mHealth Apps for Persons With Cognitive Impairment: A Systematic Review. J Med Internet Res (2017) 0.75
Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design. JAMA Neurol (2017) 0.75
Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids. FASEB J (2017) 0.75
Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plast (2017) 0.75
The A2V mutation as a new tool for hindering Aβ aggregation: A neutron and x-ray diffraction study. Sci Rep (2017) 0.75
Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep (2016) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 6.09
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA (1994) 5.98
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 5.94
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006) 5.81
Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci (1991) 5.71
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 4.40
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA (2009) 4.02
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA (1992) 3.89
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology (2005) 3.78
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA (2010) 3.58
Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol (2008) 3.28
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 3.25
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol (2007) 3.04
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA (1997) 2.80
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology (2008) 2.79
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology (2009) 2.76
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 2.76
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Tacrine in Alzheimer's disease. Lancet (1991) 2.67
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol (2008) 2.62
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology (2007) 2.54
Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther (1999) 2.53
Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology (1991) 2.53
Memantine for dementia. Cochrane Database Syst Rev (2006) 2.52
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 2.38
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev (2006) 2.31
Human memory and the cholinergic system. A relationship to aging? Arch Neurol (1974) 2.24
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol (2006) 2.16
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry (2006) 2.06
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One (2010) 1.92
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology (2004) 1.91
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement (2009) 1.79
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol (2010) 1.73
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med (2007) 1.68
Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord (1997) 1.62
A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology (2000) 1.58
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.53
Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol (2008) 1.51
Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther (1989) 1.50
Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry (2005) 1.47
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology (1996) 1.45
Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 1.43
Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol (2011) 1.42
Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev (2006) 1.37
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol (2012) 1.33
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess (2006) 1.30
Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol (2007) 1.29
A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology (1996) 1.24
Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev (2009) 1.24
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry (2011) 1.22
Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis (2008) 1.20
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs (2010) 1.20
Where, when, and in what form does sporadic Alzheimer's disease begin? Curr Opin Neurol (2012) 1.18
Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging (2009) 1.12
Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 1.07
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis (2013) 1.06
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology (2011) 1.06
Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res (2007) 1.05
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
ALSPAC--the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol (2001) 14.31
The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94
Implementing findings of research. BMJ (1994) 12.85
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Is the two week rule for cancer referrals working? BMJ (2001) 7.90
Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet (2000) 7.31
Restriction endonucleases for pulsed field mapping of bacterial genomes. Nucleic Acids Res (1987) 7.03
It's not 'just deprivation': why do equally deprived UK cities experience different health outcomes? Public Health (2010) 6.65
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Qualitative research methods in general practice and primary care. Fam Pract (1995) 5.72
Assessment of clinical competence. Lancet (2001) 5.21
Does continuing medical education in general practice make a difference? BMJ (1999) 4.40
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Gene coding assignments for growth restriction, neutralization and subgroup specificities of the W and DS-1 strains of human rotavirus. J Gen Virol (1983) 4.25
Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med (1994) 4.09
New ages for the last Australian megafauna: continent-wide extinction about 46,000 years ago. Science (2001) 3.91
Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut (2007) 3.87
Consent and confidentiality in teaching in general practice: survey of patients' views on presence of students. BMJ (1997) 3.64
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology (2010) 3.58
p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J (1991) 3.55
Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract (1989) 3.53
A study of general practitioners' reasons for changing their prescribing behaviour. BMJ (1996) 3.36
Seizure control and mortality in epilepsy. Ann Neurol (1999) 3.28
Why do qualitative research? BMJ (1995) 3.23
Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections. J Virol (1988) 3.20
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16
The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ (1999) 3.14
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Lead-contaminated soil abatement and urban children's blood lead levels. JAMA (1993) 3.06
Rescue and serotypic characterization of noncultivable human rotavirus by gene reassortment. Infect Immun (1982) 2.97
Recognition of faux pas by normally developing children and children with Asperger syndrome or high-functioning autism. J Autism Dev Disord (1999) 2.90
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology (2008) 2.79
Mental health care training priorities in general practice. Br J Gen Pract (1997) 2.79
Why do early-emerging tree seedlings have survival advantages?: a test using Acer rubrum (Aceraceae). Am J Bot (1997) 2.77
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation (1991) 2.62
General practitioners with special clinical interests. Clin Med (2001) 2.61
Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci (1997) 2.59
Evaluation of filter paper blood lead methods: results of a pilot proficiency testing program. Clin Chem (1999) 2.58
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol (2000) 2.37
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab (2013) 2.31
The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc (2001) 2.30
Validation of 24-hour recalls assisted by food records in third-grade children. The CATCH Collaborative Group. J Am Diet Assoc (1993) 2.29
Body mass index and the risk of Parkinson disease. Neurology (2006) 2.28
Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. Proc Natl Acad Sci U S A (1993) 2.27
Education and dementia: what lies behind the association? Neurology (2007) 2.26
The early detection of colorectal cancer in primary care. Br J Gen Pract (1999) 2.26
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ (1998) 2.21
Selection of the T cell repertoire. Annu Rev Immunol (1999) 2.21
Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ (1996) 2.20
Open access endoscopy. Br Med J (Clin Res Ed) (1985) 2.18
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology (1997) 2.14
Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behavior therapy, and cognitive behavior therapy. Arch Gen Psychiatry (1993) 2.12
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Rectal bleeding: prevalence and consultation behaviour. BMJ (1995) 2.11
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 2.10
Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut (1997) 2.09
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord (2006) 2.08
Assessment of the performance of five intensive care scoring models within a large Scottish database. Crit Care Med (2000) 2.08
The impact of new technology on general practice. J R Coll Gen Pract (1986) 2.08
Total cholesterol and the risk of Parkinson disease. Neurology (2008) 2.06
Hypercholesterolaemia: not all cases warrant treatment. BMJ (1993) 2.06
Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology (1991) 2.05
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Simultaneous liquid chromatographic determination of seventeen of the major monoamine neurotransmitters, precursors and metabolites. II. Assessment of human brain and cerebrospinal fluid concentrations. J Chromatogr (1987) 2.04
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Scanning electron microscopic study of virulent and avirulent colonies of Neisseria gonorrhoeae. Infect Immun (1975) 2.03
Patients' attitudes to chaperones. J R Coll Gen Pract (1985) 2.01
Experimental atherosclerosis in rhesus monkeys. II. Cellular elements of proliferative lesions and possible role of cytoplasmic degeneration in pathogenesis as studied by electron microscopy. Exp Mol Pathol (1967) 2.00
Massive Surgical Emphysema, Pneumothorax, Pneumoperitoneum. Br Med J (1945) 2.00
Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol (1997) 1.99
Variability in 28-day outcomes for very low birth weight infants: an analysis of 11 neonatal intensive care units. Pediatrics (1988) 1.99
Second gene (nifH*) coding for a nitrogenase iron protein in Azotobacter chroococcum is adjacent to a gene coding for a ferredoxin-like protein. EMBO J (1986) 1.96
Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc (1988) 1.95
A dumbbell-shaped, double-hairpin structure of DNA: a thermodynamic investigation. Biochemistry (1987) 1.92
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA (1996) 1.90
Cultivation and characterization of three strains of murine rotavirus. J Virol (1986) 1.90
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology (2010) 1.88
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Phosphoenolpyruvate carboxylase from the crassulacean plant Bryophyllum fedtschenkoi Hamet et Perrier. Purification, molecular and kinetic properties. Biochem J (1978) 1.86
The primary structure of rat ribosomal protein S12. The relationship of rat S12 to other ribosomal proteins and a correlation of the amino acid sequences of rat and yeast ribosomal proteins. J Biol Chem (1987) 1.86
Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.86